A digital intervention to improve mental health and interpersonal resilience in young people who have experienced technology-assisted sexual abuse: a feasibility clinical trial.

BACKGROUND

The purpose of the present study was to conduct a feasibility trial of i-Minds, a digital mental health intervention (DMHI) designed to improve mentalisation in young people (YP) who have experienced technology-assisted sexual abuse (TASA). Enhancing mentalisation may reduce the risk of re-victimisation, strengthen resilience, and support management of TASA-related distress. However, evidence-based interventions for TASA are nascent.

METHODS

We determined the feasibility, acceptability, and safety of a 6-week mentalisation-based DMHI for YP with TASA in a pre-registered multicentre non-randomised clinical trial (ISRCTN43130832). YP aged 12-18 years recruited across child and adolescent mental health services in two sites completed baseline and post-treatment assessments.

RESULTS

Forty-six people were recruited; 43 were allocated to the i-Minds app; 86% completed follow-up assessments. The average participant age was 15.42 years. Most participants identified as female (69.8%), White British (95.3%); a notable percentage identified as non-binary/third gender or preferred not to disclose their gender identity (16.3%), and 20.9% reported their gender did not match their sex assigned at birth. We found signals of post-treatment improvement in TASA-related post-traumatic symptoms, resilience, internalising symptoms, and reflective functioning. User feedback indicated that participants generally had a positive experience of using the app, positively impacting their knowledge/understanding of their own mental health and their motivation to address their mental health difficulties. There were no related adverse events.

CONCLUSION

It is possible to recruit and retain participants for a DMHI trial of TASA. The i-Minds app was safe, acceptable and showed promising signals of efficacy on valuable outcomes. Following further refinements, a powered efficacy trial is warranted to confirm and extend findings.